# Psychological Mobile App for Patients With AML

> **NCT05501171** · NA · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 11 (actual)

## Conditions studied

- AML
- Acute Myeloid Leukemia

## Interventions

- **BEHAVIORAL:** DREAMLAND
- **BEHAVIORAL:** CERENA

## Key facts

- **NCT ID:** NCT05501171
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-10-15
- **Primary completion:** 2023-02-01
- **Final completion:** 2023-02-01
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** the funding agency (blue note therapeutics) pulled out and did not provide funding
- **Last updated:** 2023-08-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05501171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05501171, "Psychological Mobile App for Patients With AML". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05501171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*